Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRE: Durvalumab and Tazemetostat in Multiple Solid Tumors
NCT04705818Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tazemetostat in pancreatic cancer (PC), colorectal cancer (CRC), solid tumor and 1 more (4 cohorts), sponsored by Institut Bergonié. Primary endpoint: Assessment of antitumor activity at 6 months. Started Jul 2021; status: completed.
02
Drugs
durvalumabtazemetostat
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)solid tumorsoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04705818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705818.